2018
DOI: 10.1038/s41397-018-0056-y
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacogenomics in epithelial ovarian cancer first-line treatment outcome: validation of GWAS-associated NRG3 rs1649942 and BRE rs7572644 variants in an independent cohort

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
4
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 12 publications
(4 citation statements)
references
References 40 publications
0
4
0
Order By: Relevance
“…TREM2, a novel pattern recognition receptor family member, is generally regarded to be an enhancer of immune responses (33). According to pharmacogenomics, NRG3 rs1649942 genetic variants have been validated to affect epithelial ovarian cancer first-line treatment outcomes, which confirmed patients carrying the NRG3 rs1649942 A allele presented a significantly longer OS time (34). In addition, CLC and TNFAIP6, which are cytokine receptors, are involved in disease progression and the immune response (35) in a variety of tumors, such as gastric cancer (36), breast cancer (37) and urothelial carcinomas (38).…”
Section: Discussionmentioning
confidence: 99%
“…TREM2, a novel pattern recognition receptor family member, is generally regarded to be an enhancer of immune responses (33). According to pharmacogenomics, NRG3 rs1649942 genetic variants have been validated to affect epithelial ovarian cancer first-line treatment outcomes, which confirmed patients carrying the NRG3 rs1649942 A allele presented a significantly longer OS time (34). In addition, CLC and TNFAIP6, which are cytokine receptors, are involved in disease progression and the immune response (35) in a variety of tumors, such as gastric cancer (36), breast cancer (37) and urothelial carcinomas (38).…”
Section: Discussionmentioning
confidence: 99%
“…Of interest, some candidates related to sperm and infertility were identified, containing MORC1 [46], TDRD9 [47], ZFYVE21 [48], ADGRB3 [49], SPAG17 [50,51], CKB [52], and WDR3 [53], which may have effects on sperm motility and fertilization. Additionally, we identified some candidate genes linked to reproductive diseases, such as NRG3 [54] and XRCC3 [55] for ovarian cancer, and BAG5 [56], CKB [57] and XRCC3 [55] for endometriosis. Taken together, these data indicate the importance of reproductive health in lambing.…”
Section: Candidate Genes Likely Functioning In Prolificacymentioning
confidence: 99%
“…An intronic variant of NRG1 was also found to be associated with non-small cell lung cancer survival [ 11 ]. Moreover, a polymorphism in NRG3 might lead to better overall survival in patients with stage IV epithelial ovarian cancer who are receiving first-line treatment [ 12 ]. However, the roles of genetic variants within the NRG signalling pathway in prostate cancer are unclear, and investigations into their functions may provide insight into the etiology and prognostic significance of the disease.…”
Section: Introductionmentioning
confidence: 99%